NXP Semiconductors and Enfucell unveil disruptive biopharmaceutical cold chain monitoring solution
NXP’s NHS3100 is a single chip solution for temperature logging and integrates a very accurate [0.3⁰C] temperature sensor and NFC interface
Eindhoven, Netherlands, February 3, 2015 - Biopharmaceutical products (vaccines, hormones, blood) play an increasingly important role in the pharmaceutical industry. To be effective and safe, these products have to be kept in the cold chain from production to administration. Cold chain monitoring is mostly done using either chemical temperature loggers or reusable electronic loggers, both are inadequate.
Chemical temperature loggers can only detect simple cold chain excursion and do not indicate when the event occurred. Reusable electronic loggers are expensive and bulky, therefore only deployed at pallet and not item level. Moreover it is cumbersome to recycle them.
NXP and Enfucell have jointly developed a disposable temperature logging foil demonstrator. This solution supports logging functionality similar to that of a reusable logger, but form factor and product cost do enable item level logging. The foil contains NXP’s NHS3100 IC, Enfucell’s printed battery and an NFC antenna.
NXP’s NHS3100 is a single chip solution for temperature logging. It integrates a very accurate [0.3⁰C] temperature sensor, an NFC interface, an accurate time reference, a non-volatile temperature logging memory and programmable Cortex M0+ processor. The programmable architecture offers biopharmaceutical manufacturers the option to define a product-specific temperature excursion limit profile. Different from the simple caloric model used in chemical loggers, the more elaborate profile can minimize product waste in the logistic chain. The internal time reference offers traceability across the logistics chain of exposure beyond excursion limits. The embedded NFC interface supports read-out of the product’s status by means of an NFC-enabled smart phone or reader, at any point in the logistic chain or by medical staff administering the product.
Enfucell’s battery technology offers a thin, flexible and eco-friendly power source which can be printed onto the flexible foil. The demonstrator’s battery capacity, along with the ultra-low power characteristics of NHS3100, offers a shelf life of 1 year, and supports active logging for 2 years after activation.
This solution will support reduction of biopharmaceutical waste, increase safety and efficacy of biopharmaceutical products, provide visibility when and where the product was handled incorrectly.
The foil can be used as starting point for your design of a flexible temperature logging tag. Contact NXP (email@example.com) if you like to evaluate the NHS3100.
About NXP Semiconductors
NXP Semiconductors N.V. (NASDAQ: NXPI) creates solutions that enable secure connections for a smarter world. Building on its expertise in High Performance Mixed Signal electronics, NXP is driving innovation in the automotive, identification and mobile industries, and in application areas including wireless infrastructure, lighting, healthcare, industrial, consumer tech and computing. NXP has operations in more than 25 countries, and posted revenue of $4.82 billion in 2013. Find out more at www.nxp.com.
Enfucell is a leading customized battery supplier to printed electronics industry. The company has developed SoftBattery®, a thin, flexible and eco-friendly printed power source. SoftBattery® can be utilized optimally in disposable products. Main application areas include transdermal delivery systems, wireless micro sensors, medical and healthcare products including functional packaging of those. Enfucell’s customers and partners include many of the world’s leading corporations in their fields. Enfucell business model is based on licensing the technology to manufacturing partners around the world. Find out more at www.enfucell.com.
This document includes forward-looking statements which include statements regarding NXP’s business strategy, financial condition, results of operations and market data, as well as other statements that are not historical facts. By their nature, forward-looking statements are subject to numerous factors, risks and uncertainties that could cause actual outcomes and results to be materially different from those projected. Readers are cautioned not to place undue reliance on these forward-looking statements. Except for any ongoing obligation to disclose material information as required by the United States federal securities laws, NXP does not have any intention or obligation to publicly update or revise any forward-looking statements after NXP distributes this document, whether to reflect any future events or circumstances or otherwise. For a discussion of potential risks and uncertainties, please refer to the risk factors listed in NXP’s SEC filings. Copies of NXP’s SEC filings are available from the SEC website, www.sec.gov.
For further press information, please contact:
Europe: Martijn van der Linden,+31 6 10914896, firstname.lastname@example.org
Greater China/Asia: Esther Chang, +886 2 8170 9990, email@example.com
Americas: Hillary Cain, +1 408 518 5227, firstname.lastname@example.org
Anja Talo, +358 45 123 2511, email@example.com